ENHANCING ONCOLOGICAL VIGILANCE AND EARLY DIAGNOSIS IN PATIENTS AT HIGH RISK OF HEAD AND NECK TUMORS

Authors

Keywords:

head and neck tumors; ENT oncology; oncological vigilance; early diagnosis; risk factors; screening; biopsy; Uzbekistan; CIS; multidisciplinary care.

Abstract

Background: Head and neck malignancies are clinically heterogeneous and often present first to primary care physicians, dentists, or otorhinolaryngologists rather than oncology specialists. Delayed recognition of alarm symptoms and fragmented referral pathways may postpone morphological verification. Objective: To synthesize current evidence on risk factors, early detection, diagnostic delay, and interdisciplinary referral in tumors of the ear, nose, and throat (ENT) organs and adjacent head and neck regions, with particular emphasis on Uzbekistan and other Commonwealth of Independent States (CIS) countries, and to formulate a practical risk-oriented diagnostic algorithm. Methods: A narrative review of 40 sources published between 2005 and 2025 was performed. The evidence base included international epidemiological reports, systematic reviews and meta-analyses, clinical guidelines, professional society recommendations, original studies, and regional publications. Particular attention was given to tobacco- and alcohol-related risk, potentially malignant oral disorders, HPV- and EBV-associated disease, endoscopy, narrow-band imaging, biopsy techniques, and organizational causes of diagnostic delay. Results: Current evidence does not support universal population-based screening for all head and neck tumors. In contrast, risk-oriented active case finding is clinically relevant in individuals with tobacco and alcohol exposure, potentially malignant mucosal lesions, persistent dysphonia or dysphagia, unexplained cervical lymphadenopathy, and other warning signs. Endoscopy and appropriately selected biopsy remain central to diagnostic confirmation, while p16/HPV and EBV-related testing are valuable in defined clinical settings. Available data from Uzbekistan and CIS countries indicate regional disparities, late-stage presentation, and dependence of outcomes on the quality and speed of the initial diagnostic pathway. Conclusion: A standardized multidisciplinary pathway based on risk assessment, recognition of red-flag symptoms, prompt endoscopy, tissue verification, selective molecular testing, and quality auditing may strengthen oncological vigilance and reduce avoidable diagnostic delay, particularly in health systems with uneven access to specialized services.

 

References

1.Lima AM, Meira IA, Soares MS, et al. Delay in diagnosis of oral cancer. Med Oral Patol Oral Cir Bucal. 2021;26:e815–e824.

2.Lauritzen BB, Jensen JS, Grønhøj C, et al. Impact of delay in diagnosis and treatment-initiation on oral cavity cancer. Acta Oncol. 2021;60:1083–1090.

3.Saka C, Jané E, Marí A, et al. Time-to-Treatment in Oral Cancer. Cancers. 2021;13:1321.

4.Sankaranarayanan R, Ramadas K, Thomas G, et al. Effect of screening on oral cancer mortality in Kerala. Lancet. 2005;365:1927–1933.

5.Cheung LC, Ramadas K, Muwonge R, et al. Risk-Based Selection of Individuals for Oral Cancer Screening. J Clin Oncol. 2021;39:663–674.

6.Walsh T, Warnakulasuriya S, Lingen MW, et al. Clinical assessment for detection of oral cavity cancer. Cochrane Database Syst Rev. 2021;12:CD010173.

7.Parak U, Lopes Carvalho A, Roitberg F, Mandrik O. Effectiveness of screening for oral cancer and OPMD. Prev Med Rep. 2022;30:101987.

8.Guntinas-Lichius O, et al. Targeted Screening Strategies for Head and Neck Cancer. Diagnostics. 2025;15:2095.

9.Chabrillac E, Dupret-Bories A, Vairel B, et al. Narrow-Band Imaging in oncologic otorhinolaryngology. Eur Ann Otorhinolaryngol Head Neck Dis. 2021;138:451–458.

10.Galli J, Settimi S, Mele DA, et al. Role of Narrow Band Imaging in laryngeal lesions. J Clin Med. 2021;10:1224.

11.Wagner JM, et al. Ultrasound-Guided Fine-Needle Aspiration with optional core biopsy. J Ultrasound Med. 2019;38:2275–2284.

12.Cabezas-Camarero S, Pérez-Segura P. Liquid Biopsy in Head and Neck Cancer. Cancers. 2022;14:2858.

13.Bastías D, Maturana A, Marín C, et al. Salivary Biomarkers for Oral Cancer Detection. Int J Mol Sci. 2024;25:2634.

14.Lewis JS, Beadle B, Bishop JA, et al. HPV testing in head and neck carcinomas guideline. Arch Pathol Lab Med. 2018;142:559–597.

15.Lewis JS, Beadle B, Bishop JA, et al. HPV Testing Guideline Update. Arch Pathol Lab Med. 2025;149:e115–e150.

16.Chan KCA, Woo JKS, King A, et al. Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. N Engl J Med. 2017;377:513–522.

17.Lee VHF, Adham M, Ben Kridis W, et al. International recommendations for plasma EBV DNA measurement. Lancet Oncol. 2022;23:e544–e551.

18.International Agency for Research on Cancer. Uzbekistan Fact Sheet. Global Cancer Observatory. Lyon: IARC; 2024.

19.Khazratov AI, Rizaev JA, Alieva DA, Ganiev AA. Study of regional characteristics of oral cancer incidence in the Republic of Uzbekistan. Doktor Akhborotnomasi. 2024;3(115):104–108.

20.Nurov ZhR. Epidemiology of pharyngeal cancer in the Bukhara region. Bulletin of Fundamental and Clinical Medicine. 2024;6(12):109–113.

21.Clinical Guidelines. Laryngeal Cancer. Association of Oncologists of Russia, Russian Society of Clinical Oncology, Russian Society of Specialists in Head and Neck Tumors. 2024.

22.Ahmedin D, Makishev A, Telmanova Z, et al. Hypopharynx Cancer Incidence in Kazakhstan: 2017–2021. Asian Pac J Cancer Prev. 2023;24:4043–4051.

23.Shlyaga ID, Kolyadich ZhV, Ivanov SA, Evmenenko AA. Epidemiological analysis of malignant neoplasms of the larynx in Belarus, 2000–2019. Problems of Health and Ecology. 2021;18(4):83–92.

Published

2026-09-25